Phase II trial of gemcitabine in refractory germ cell tumors

Lawrence Einhorn, Michael J. Stender, Stephen D. Williams

Research output: Contribution to journalArticle

125 Citations (Scopus)

Abstract

Purpose: This phase II study was designed to determine the toxicity and activity of single-agent gemcitabine in heavily pretreated patients with germ cell tumors. Patients and Methods: From March 1996 through November 1997, 21 patients were enrolled onto a phase II study of gemcitabine 1,200 mg/m2, given on clays 1, 8, and 15 every 4 weeks. One patient was unassessable because he never received any gemcitabine. Thirteen of 20 patients had received three prior regimens, and 13 patients were platinum refractory (progression during or within 4 weeks of platinum treatment). There were five extragonadal cases and two patients with late relapse (relapse beyond 2 years). Results: Gemcitabine was well tolerated. Only one patient had grade 3 or 4 nonhematologic toxicity (grade 3 nausea). Six of 20 patients had grade 3 leukopenia. There were no episodes of granulocytopenic fever, and no patient required platelet transfusion. Three (15%) of 20 patients achieved an objective response, including one complete remission. Three additional patients had a minor radiographic or serologic response. Conclusion: Gemcitabine had definite activity in this heavily pretreated germ cell tumor patient population.

Original languageEnglish
Pages (from-to)509-511
Number of pages3
JournalJournal of Clinical Oncology
Volume17
Issue number2
StatePublished - Feb 1999

Fingerprint

gemcitabine
Germ Cell and Embryonal Neoplasms
Platinum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II trial of gemcitabine in refractory germ cell tumors. / Einhorn, Lawrence; Stender, Michael J.; Williams, Stephen D.

In: Journal of Clinical Oncology, Vol. 17, No. 2, 02.1999, p. 509-511.

Research output: Contribution to journalArticle

Einhorn, L, Stender, MJ & Williams, SD 1999, 'Phase II trial of gemcitabine in refractory germ cell tumors', Journal of Clinical Oncology, vol. 17, no. 2, pp. 509-511.
Einhorn, Lawrence ; Stender, Michael J. ; Williams, Stephen D. / Phase II trial of gemcitabine in refractory germ cell tumors. In: Journal of Clinical Oncology. 1999 ; Vol. 17, No. 2. pp. 509-511.
@article{867866be306e4fd09ebfab370d9f80ce,
title = "Phase II trial of gemcitabine in refractory germ cell tumors",
abstract = "Purpose: This phase II study was designed to determine the toxicity and activity of single-agent gemcitabine in heavily pretreated patients with germ cell tumors. Patients and Methods: From March 1996 through November 1997, 21 patients were enrolled onto a phase II study of gemcitabine 1,200 mg/m2, given on clays 1, 8, and 15 every 4 weeks. One patient was unassessable because he never received any gemcitabine. Thirteen of 20 patients had received three prior regimens, and 13 patients were platinum refractory (progression during or within 4 weeks of platinum treatment). There were five extragonadal cases and two patients with late relapse (relapse beyond 2 years). Results: Gemcitabine was well tolerated. Only one patient had grade 3 or 4 nonhematologic toxicity (grade 3 nausea). Six of 20 patients had grade 3 leukopenia. There were no episodes of granulocytopenic fever, and no patient required platelet transfusion. Three (15{\%}) of 20 patients achieved an objective response, including one complete remission. Three additional patients had a minor radiographic or serologic response. Conclusion: Gemcitabine had definite activity in this heavily pretreated germ cell tumor patient population.",
author = "Lawrence Einhorn and Stender, {Michael J.} and Williams, {Stephen D.}",
year = "1999",
month = "2",
language = "English",
volume = "17",
pages = "509--511",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Phase II trial of gemcitabine in refractory germ cell tumors

AU - Einhorn, Lawrence

AU - Stender, Michael J.

AU - Williams, Stephen D.

PY - 1999/2

Y1 - 1999/2

N2 - Purpose: This phase II study was designed to determine the toxicity and activity of single-agent gemcitabine in heavily pretreated patients with germ cell tumors. Patients and Methods: From March 1996 through November 1997, 21 patients were enrolled onto a phase II study of gemcitabine 1,200 mg/m2, given on clays 1, 8, and 15 every 4 weeks. One patient was unassessable because he never received any gemcitabine. Thirteen of 20 patients had received three prior regimens, and 13 patients were platinum refractory (progression during or within 4 weeks of platinum treatment). There were five extragonadal cases and two patients with late relapse (relapse beyond 2 years). Results: Gemcitabine was well tolerated. Only one patient had grade 3 or 4 nonhematologic toxicity (grade 3 nausea). Six of 20 patients had grade 3 leukopenia. There were no episodes of granulocytopenic fever, and no patient required platelet transfusion. Three (15%) of 20 patients achieved an objective response, including one complete remission. Three additional patients had a minor radiographic or serologic response. Conclusion: Gemcitabine had definite activity in this heavily pretreated germ cell tumor patient population.

AB - Purpose: This phase II study was designed to determine the toxicity and activity of single-agent gemcitabine in heavily pretreated patients with germ cell tumors. Patients and Methods: From March 1996 through November 1997, 21 patients were enrolled onto a phase II study of gemcitabine 1,200 mg/m2, given on clays 1, 8, and 15 every 4 weeks. One patient was unassessable because he never received any gemcitabine. Thirteen of 20 patients had received three prior regimens, and 13 patients were platinum refractory (progression during or within 4 weeks of platinum treatment). There were five extragonadal cases and two patients with late relapse (relapse beyond 2 years). Results: Gemcitabine was well tolerated. Only one patient had grade 3 or 4 nonhematologic toxicity (grade 3 nausea). Six of 20 patients had grade 3 leukopenia. There were no episodes of granulocytopenic fever, and no patient required platelet transfusion. Three (15%) of 20 patients achieved an objective response, including one complete remission. Three additional patients had a minor radiographic or serologic response. Conclusion: Gemcitabine had definite activity in this heavily pretreated germ cell tumor patient population.

UR - http://www.scopus.com/inward/record.url?scp=0033015208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033015208&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 509

EP - 511

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -